nursing drug cards

7/24/2019 Nursing Drug Cards

1/32

Trade Name:Cipro

Classifcation:Broad-Spectrum Antiinfectives

Use(s):Infections caused by susceptible organisms E

Proteus, staph.

Action:Interferes ith conversion of !"A fragments in

higher molecular eight ones. !"A gyrase inhibitors.

Contraindications:#ypersensitivity to $uinolones

Side Eects:#eadache, di%%iness, restlessness, "&'&!

Nursing implications: Assess for C"S symptoms, I()ratio, allergic reactions.


2/32

*E++)S S*AE

CLASSIFICATIN:Antianemic, iron

ACTIN:"ormal daily inta/e males 01-12 mg3 females 4-05 m

only 026 absorbed3 Iron absorbed by from duodenum and upp

7e7unum by active mechanism thru mucosal cells, combines it

transferring3 iron stored as hemosiderin or aggregated ferritin c

of liver, spleen, bone marro3 1&8 of iron in circulating +BC9s

IN!ICATINS:Prophyla:is, treatment of iron de;ciency and irde;ciency anemia9s3 dietary supplement for iron

USUAL !SA"E:Adults 822 mg&day

A!#E$SE $EACTINS< Constipation, gastric irritation, nausea

abdominal cramps, anore:ia, diarrhea, dar/-colored stools

NU$SIN" CNSI!E$ATINS< Substitution of one iron salt foranother ithout proper ad7ustment may result in serious over o


3/32

under dosing3 Eggs, mil/, co=ee or tea may signi;cantly inhibit

absorption.

A>)?ICII"

CLASSIFICATIN< Antibiotic, penicillin

ACTIN:Synthetic broad-spectrum penicillin closely related to

ampicillin3 Binds to bacterial cell all @PBP-0 and PBP-83 penicil

binding sites, causing cell death by inhibiting cell all synthes

bactericidal action3 spectrum is larger than penicillin9sIN!ICATINS:Ear, nose, and throat infections.

USUAL !SA"E:

)ver 2 /g< 522 mg $4hr or 522 mg $01hr3 under 2 /gI")P#E"

CASSI*ICAI)"< non-narcotic analgesic


5/32

ACI)"< !ecreases fever by 0 a hypothalamic e=ect leading to sand vasodilation and 1 inhibits the e=ect of pyrogens on thehypothalamic heat-regulating centers. >ay cause analgesia by inC"S prostaglandin synthesis3 hoever, due to minimal e=ects on

peripheral prostaglandin synthesis, acetaminophen has no anti-inammatory or uricosuric e=ects. !oes not cause any anticoague=ect or ulceration of the DI tract. Antipyretic and analgesic e=eccomparable to those of aspirin.I"!ICAI)"S< 0 Control of pain 1 +educes fever in bacterial or vinfections

SA !)SADE< Adults< 815-52 mg $hrA!'E+SE +EACI)"S< *e hen ta/en in usual therapeutic dose

upset in some3 Chronic and even acute to:icity can develop after

symptom-free usage

I"E+ACI)"S< Chronic Et)# F to:icity of larger therapeutic dos

barbiturates, carbama%epine, hydantoins, isonia%id, rifampin (

sul;npyra%one< F hepatoto:icity potential related to F liver brea


6/32

%G!+)C#)+)#IAHI!E

CLASSIFICATIN< Antihypertensive, combination drug

ACTIN< acts directly on the distal tubule to promote the e:cretiof sodium, bicarbonate, chloride, and uid3 Increases urinary p#3

#ydrochlorothia%ide promotes e:cretion of sodium and chloride a

ater by distal renal tubule3 Also increases e:cretion of potassium

smaller amounts of bicarbonate3 Antihypertensive e=ects due to

dilation of arterioles as ell as uid volume lossIN!ICATINS< #ypertension or edema in clients ho manifest

hypo/alemia on hydrochlorothia%ide alone3 in clients re$uiring a

and in hom hypo/alemia cannot be ris/ed3 usually not ;rst line

therapy e:cept hen avoiding hypo/alemia

A!#E$SE $EACTINS< "ausea ( vomiting, headache, anore:iaupset, diarrhea, atulence, di%%iness, photosensitivity


7/32

NU$SIN" CNSI!E$ATINS< Assess for alcoholism, monitor vi

signs and tests @reduce dose ith dysfunction3 drug is ta/en to lo

and reduce selling of e:tremities @ta/e in A> ith food to reduc

upset. rash, fever

A>)SI" #G!+)C#)+I!E

CLASSIFICATIN< Alpha-adrenergic bloc/ing drug

ACTIN< Bloc/ade of alpha0-receptors @probably alpha0a in the

prostateresults in rela:ation of smooth muscles in the bladder, ne

prostate3thus, urine o rate is improved and there is a decrease

symptoms of BP#IN!ICATINS< Signs and symptoms of BP#3 rule-out prostatic ca

before using tamsulosin

A!#E$SE$EACTINS< #eadache, di%%iness, pharyngitis&rhinitis

shoulder&nec/&bac/&e:tremity pain, asthenia, diarrhea, chest pain

NU$SIN"CNSI!E$ATINS< identify drugs prescribed to ensuof the drugs interact, especially cimetidine or Coumadin3 monitor


8/32

I(), 'S, eight, urodynamic studies3 note PSA levels, results of

digital rectal e:am3 ta/e as directed, do not che, crush, or open

Atenolol @enorminCLASSIFICATIN< Beta-Bloc/er

ACTIN< In therapeutic doses, atenolol selectively bloc/s beta0-

adrenergic receptors located chiey in cardiac muscle.

IN!ICATINS used to treat high blood pressure. It is also used t

angina and chest pain.A!#E$SE $EACTINS< Constipation, indigestion, dry mouth, di%

NU$SIN" CNSI!E$ATINS: Chec/ apical pulse before giving

drug, especially in patients receiving digitalis @both drugs slo A'

conduction. If belo 2 bpm @or other ordered parameter, ithh

and consult physician. >onitor apical pulse, BP, respirations, and


9/32

peripheral circulation throughout dosage ad7ustment period. Con

physician for acceptable parameters.

E"AAP+I >AEAE @'asotec

CLASSIFICATIN< CA+!I)'ASCA+ ADE"3 A"DI)E"SI"-C)"

E"HG>E @ACE I"#IBI)+3 A"I#GPE+E"SI'E

ACTIN< Angiotensin-converting en%yme @ACE inhibitor. ACE catthe conversion of angiotensin I to angiotensin II, a vasoconstricto

substance. herefore, inhibition of ACE decreases angiotensin II l

hich decreases vasopressor activity and aldosterone secretion.

IN!ICATINS >anagement of mild to moderate hypertension.

A!#E$SE $EACTINS


10/32

NU$SIN" CNSI!E$ATINS: >onitor BP for ;rst several days

therapy. If antihypertensive e=ect is diminished before 1 h, the

dose may be given as 1 divided doses. +eport transient hypotens

lightheadedness. )lder adults are particularly sensitive to drug-in

hypotension. Supervise ambulation until BP has stabili%ed.ab tests< >onitor serum potassium and be alert to symptoms of

hyper/alemia @J K5.L mE$&.

PA")P+AH)E

CLASSIFICATIN< DAS+)I"ESI"A ADE"3 P+))" P>P I"ACTINDastric acid pump inhibitor3 belongs to a class of antisecompounds. Dastric acid secretion is decreased by inhibiting the

APase en%yme system responsible for acid production.

IN!ICATINS Short-term treatment of erosive esophagitis assoc

ith gastroesophageal reu: disease @DE+!.A!#E$SE $EACTINS< !iarrhea, atulence, abdominal pain.


11/32

NU$SIN" CNSI!E$ATINS: >onitor for and immediately repo

angioedema or a severe s/in reaction. ab tests< rea breath test

after completion of therapy.

!IC)*E"AC S)!I>

CLASSIFICATIN< CE"+A "E+')S SGSE> ADE"3 A"ADES

A"IPG+EIC3 "SAI!ACTIN< Although its e:act mechanism of action has not been fu

elucidated, it appears to be a potent inhibitor of cycloo:ygenase,

decreasing the synthesis of prostaglandins.

IN!ICATINS Analgesic and antipyretic e=ects in symptomatic t

of rheumatoid arthritis, osteoarthritis, and an/ylosing spondylitis

acute gout.


12/32

A!#E$SE $EACTINSonitor BP for hypertension and b

sugar for hyperglycemia.


13/32

0. Acute pain related to< inammation and infection of the urethr

bladder and other urinary tract structures.

1. #yperthermia related to< inammatory reaction

8. Impaired rinary Elimination related to< fre$uent urination, urg

hesitancy

. +is/ for *luid 'olume !e;citrelated to< e:cessive evaporation

vomiting

5. !isturbed Sleep Pattern related to< pain and nocturia.

. noledge !e;cit< about condition, prognosis, and treatment

related toonitor input and output characteristics of the urine.+ational< provides information about renal function and presence of complications

1 !etermine the patientNs voiding patterns

8 Encourage increased uid inta/e+ationale< increased hydration ill ush the bacteria.

+evie the full bladder complaints+ational< urinary retention may occur causing tissue distension @bladder & /idney

5 )bservations of changes in mental status


15/32

L Collaborationonitor laboratory tests< electrolytes, creatinine+ational< control of renal dysfunction

#EPA+I"

CLASSIFICATIN< #eparin, Anticoagulant

ACTIN< !oes not dissolve previously formed clots, but forestalls enlargement and preve

from forming3 Potentiates inhibitory action of antithrombin III3 )ccurs due to formation of a

ith antithrombin III and causing a conformational change in antithrombin III molecule3 Ac

thrombin in coagulation is inhibited3 Also prevents formation of a stable ;brin clot by inhib

activation of ;brin-stabili%ing factor by thrombin

IN!ICATINS< Pulmonary&peripheral arterial embolism3 Prophyla:is and treatment of ven

thrombosis and e:tensions3 Atrial ;brillation ith emboli%ation3 reatment and diagnosis o

doses to prevent !' and PE in pregnant clients ith thromboembolism history and other

Prophyla:is of clotting in blood transfusions and others

A!#E$SE $EACTINS< #emorrhage ranging from minor local ecchymoses to ma7or hem

complications from any organ, chills, fever, urticaria, local irritation, erythema, mild pain,

INTE$ACTINS3 administer by deep sub in7ection t

local irritation, hematoma, and tissue sloughing and to prolong drug action3 utili%e H-trac/

QBunch techni$ue9 method3 do not administer ithin 1in of umbilicus @decreased vasculari

massage site, slight discoloration does not a=ect potency3 perform test dose @0,222 units

clients ith allergies or asthma history

"ENE$IC NA&E< >E)P+)) A++AE

CLASSIFICATIN< Beta-adrenergic Bloc/ing Agent

ACTIN< Combines reversibly mainly ith beta-adrenergic receptors to bloc/ the respons

sympathetic nerve impulses, circulating catecholamines, or adrenergic drugs3 Bloc/age of

receptors decreases heart rate, myocardial contractility, and cardiac output and slos A'

all of hich decreases blood pressure


17/32

IN!ICATINS< #ypertension3 Acute >I in hemodynamically stable patients3 Angina pecto

A!#E$SE $EACTINS< *atigue, di%%iness, depression, shortness of breath, bradycardia,

CNT$AIN!ICATINS< >I in clients ith a heart rate of less than 5 bpm, in second- or

heartbloc/, or if SBP is less than 022 mm #g3 moderate to severe cardiac failure

NU$SIN" CNSI!E$ATINS< !o not confuse metoprolol ith metoclopramide, metapro

misoprostol3 if transcient orsening of heart failure occurs, treat ith increased doses of d

need to loer dose of metoprolol or temporarily discontinue3 for C#*, do not increase dos

symptoms of orsening C#* have been stabili%ed3 if C#* clients e:perience symptomatic

reduce dose3 ta/e dose each day at same time3 do not stop suddenly

'itamin !

IN!ICATINS< management of hypocalcemia and resultant metabolic bone disease in pa

undergoing chronic renal dialysis3 indicated in management of secondary hyperparathyro

resultant metabolic bone disease in patients ith mild&moderate&severe chronic renal failu

dialysis3 management of hypocalcemia and clinical manifestations in patients ith postsu

hypoparathyroidism, idiopathichypoparathyroidism, and pseudohypoparathyroidism


18/32

A!#E$SE$EACTINS< #ypercalcemia syndrome or calcium into:ication3 ea/ness, hea

somnolence, "(', dry mouth, constipation, muscle pain, bone pain, metallic taste, anore:

pain, abdominal pain3 polyuria, polydipsia, nocturia, calci;c con7unctivitis, pancreatitis, ph

rhinorrhea, pruritis, hyperthermia, decreased libido, elevated B", albuminuria, hypercho

elevated SD) @AS and SDP @A and >A"G >)+E

CNT$AIN!ICATINS< Should not be ta/en to patients ith hypercalcemia or evidence

to:icity3 use in patients ith /non hypersensitivity to +ocaltrol @or drugs of same class o

inactive ingredients is contraindicated

NU$SIN"CNSI!E$ATINS< E=ectiveness is predicated on the assumption that each p

receiving an ade$uate daily inta/e of calcium3 advise patients to have dietary inta/e mini

mg daily3 patients should be advised of compliance ith dosage instructions and adheren

instructions about diet and calcium supplementation3 advise avoidance of the use of unap

nonprescription drugs3 carefully inform about S(S of hypercalcemia

"ENE$IC NA&E< ASPI+I" @ACEGSAICGCIC ACI!, ASA

CLASSIFICATIN< "onsteroidal, anti-inammatory drug, analgesic, antipyretic

ACTIN< E:hibits antipyretic, anti-inammatory, and analgesic e=ects3 Antipyretic due to

the hypothalamus, resulting in heat loss by vasodilation of peripheral blood vessels and p


19/32

seating3 Anti-inammatory mediated through inhibition of cyclo-o:ygenase, hich result

decrease in prostaglandin synthesis and other mediators of pain response

IN!ICATINS< Analgesic M Pain from integumentary structures, myalgias, neuralgias,arth

headache, dysmenorrheal, and similar types of pain3 gout3 Antipyretic, Anti-inammatory

osteoarthritis, SE, acute rheumatic fever, gout, and many other conditions

A!#E$SE $EACTINS< !yspepsia, nausea, epigastric, discomfort

CNT$AIN!ICATINS< #ypersensitivity to salicylates3 clients ith asthma, hay fever, or

have higher incidence of hypersensitivity3 severe anemia, history of blood coagulation def

con7unction ith anticoagulant therapy3 vitamin de;ciency

NU$SIN" CNSI!E$ATINS

< Enteric-coated or bu=ered tablets better tolerated by some3 ta/e ith full glass of ater3

epinephrine to counteract hypersensitivity3 ta/e temperature 0 hour after administering3 n

asthma, hay fever, ulcer disease or nasal polyps3 ta/e as directed3 administer ith meals

ater

"ENE$IC NA&E< >E*)+>I" #G!+)C#)+I!E

CLASSIFICATIN< )ral Antidiabetic, Biguanide


20/32

ACTIN< !ecreases hepatic glucose production, decreases intestinal absorption of glucos

peripheral upta/e and utili%ation of glucose3 does not cause hypoglycemia in either diabet

diabetic clients, and does not cause hyperinsulinemia3 insulin secretion remains unchange

fasting insulin levels and day-long plasma insulin response may decrease

IN!ICATINS< As monotherapy, as ad7unct to diet and e:ercise, to improve glycemic con

ith type 1 diabetes3 Immediate-release tablets and P) solution can be used in clients 02

older3 E:tended +elease form used to treat type 1 diabetes as initial therapy or in con7unc

sulfonylurea or insulin in clients 0L y&o and older

A!#E$SE $EACTINS< actic acidosis, hypoglycemia, diarrhea, nausea ( vomiting, asth

atulence, headache, abdominal pain&discomfort

NU$SIN" CNSI!E$ATINS< actic acidosis is a rare, but serious, metabolic complicati

occur due to metformin accumulation @52 6 fatal3 do not confuse Dlucophage ith Dluco

individuali%e dosage based on tolerance and e=ectiveness3 give ith meals and start at a

ith gradual escalation @ill reduce DI side e=ects3 may safely sitch

from metformin to metformin e:tended-release3 may cause a metallic taste @ill subside

"ENE$IC NA&E< Candesartan


21/32

CLASSIFICATIN< A+B

ACTIN< Angiotensin II receptor @type A0 antagonist. Angiotensin II is a potent vasocons

primary vasoactive hormone of the reninMangiotensinMaldosterone system. Candesartan s

bloc/s binding of angiotensin II to the A0 receptors found in many tissues @e.g., vascular

muscle, adrenal glands.

IN!ICATINSreating high blood pressure alone or ith other medicines. It is used in cepatients to treat heart failure. It may also be used for other conditions as determined by y

Candesartan is an angiotensin II receptor bloc/er @A+B. It or/s by rela:ing blood vessels

to loer blood pressure.

A!#E$SE $EACTINS< upper respiratory tract infection, di%%iness, bac/ pain, pharyngiti

NU$SIN" CNSI!E$ATINS< >onitor BP as therapeutic e=ectiveness is indicated by de

systolic and diastolic BP ithin 1 / ith ma:imal e=ect at M /. >onitor for transient h

in volume&salt-depleted patients3 if hypotension occurs, place in supine position and notify

>onitor BP periodically3 trough readings, 7ust prior to the ne:t scheduled dose, should be

possible. ab tests< Periodically monitor B" and creatinine, serum potassium, liver en%ym

ith di=erential.


22/32

"ENE$IC NA&E< Candesartan

CLASSIFICATIN< A+B

ACTIN< Angiotensin II receptor @type A0 antagonist. Angiotensin II is a potent vasocons

primary vasoactive hormone of the reninMangiotensinMaldosterone system. Candesartan sbloc/s binding of angiotensin II to the A0 receptors found in many tissues @e.g., vascular

muscle, adrenal glands.

IN!ICATINSreating high blood pressure alone or ith other medicines. It is used in cepatients to treat heart failure. It may also be used for other conditions as determined by y

Candesartan is an angiotensin II receptor bloc/er @A+B. It or/s by rela:ing blood vessels

to loer blood pressure.

A!#E$SE $EACTINS< upper respiratory tract infection, di%%iness, bac/ pain, pharyngiti

NU$SIN" CNSI!E$ATINS< >onitor BP as therapeutic e=ectiveness is indicated by de

systolic and diastolic BP ithin 1 / ith ma:imal e=ect at M /. >onitor for transient h

in volume&salt-depleted patients3 if hypotension occurs, place in supine position and notify

>onitor BP periodically3 trough readings, 7ust prior to the ne:t scheduled dose, should be


23/32


24/32


25/32

food to decrease DI upset3 do not share drugs3 /eep in safe place3 drug may cause di%%ine

drosiness3 may cause constipation, nausea( vomiting, rash&itching, and physical depend

alcohol and any other C"S depressants ithout provider approval3 tolerance may occur

)"!A"SE+)" #G!+)C#)+I!E

CASSI*ICAI)"< Antiemetic

ACI)"< Cytoto:ic chemotherapy is thought to release serotonin from enterochromaRn ce

small intestine3 the released serotonin may stimulate the vagal a=erent nerves through th

receptors, thus stimulating the vomiting ree:3 )ndansetron, a 5-#8 antagonist, bloc/s t

serotonin3 hether the drug acts centrally and&or peripherally to antagoni%e the e=ect of s

not /non

I"!ICAI)"S< Prevent "(' resulting from initial and repeated courses of cancer chemothe

including cisplatin, greater than 52 mg&m13 prevent "(' associated ith initial and repea

moderately emetogenic cancer chemotherapy3 Prevent "(' associated ith radiotherapy

receiving either total body irradiation, single high-dose fraction to the abdomen, or daily f

the abdomen

A!'E+SE +EACI)"S< !iarrhea, headache, di%%iness, malaise&fatigue, constipation, brady

hypotension, drosiness& sedation, an:iety&agitation, gynecological disorder, urinary reten

hypo:ia, pruritus, pyre:ia, shivers


26/32

"+SI"D C)"SI!E+AI)"S< !o not confuse Hofran ith Holoft, Hantac, or Hosyn3 do not e

P) or 4 mg I' daily ith impaired hepatic function3 1 mg&m )ndansetron in7ection re$uir

for administration for postop "('3 inspect visually for particulate matter and discoloration

administering3 drug is to prevent "('3 to be given e:actly as prescribed3 may cause dro

di%%iness3 do not perform activities that re$uire mental alertness until drug e=ects reali%ed

rash, diarrhea, constipation, altered respirations @brochospasms, or loss of response

ALEN!$NATE

CLASSIFICATIN< BISP#)SP#)"AE3 +EDA)+, B)"E >EAB)IS>

ACTIN< Alendronate is a bisphosphonate that inhibits osteoclast-mediated bone resorpti

Antiresorption mechanism is not fully understood. It does, hoever, locali%e preferentiallysites of active bone turnover and has minimal to no interference ith bone minerali%ation

IN!ICATINS< Prevention and treatment of osteoporosis in postmenopausal omen, Pag

reatment of glucocorticoid-induced osteoporosis.

A!#E$SE $EACTINSEndocrine:#ypocalcemia, hypophosphatemia. "I:Esophageal i

and ulceration, nausea, vomiting, abdominal pain, dyspepsia,diarrhea, constipation,

atulence. t'er: Arthralgias, myalgias, headache, rash.

INTE$ACTINS

!rug:$anitidineincreases alendronate availability. Food:Calciuman@especially dairy products reduce alendronate absorption.


27/32

CNT$AIN!ICATINS< #ypersensitivity to alendronate or other bisphosphonates3 severe

impairment @Clcr85 m&min3 hypocalcemia3 abnormalities3 lactation, pregnancy @category

NU$SIN" CNSI!E$ATINSonitor albumin-ad7usted serum calcium, serum phosphate, serum al/aline pho

fasting and 1 h urinary calcium, and serum electrolytes. Periodically monitor renal and liv

!iagnostic test< Bone density scan every 01M04 mo.

!iscontinue drug if the Clcr85 m&min.

"ENE$IC NA&E< CACI> CA+B)"AE

CLASSIFICATIN< Calcium salt

ACTIN< Calcium is essential for maintaining normal function of nerves, muscles, the s/eand permeability of cell membranes and capillaries3 normal serum calcium level is T-02. 5.1 mE$&. #ypocalcemia is characteri%ed by muscular ;brillation, titching, s/eletal musleg cramps, titanic spasms, cardiac arrythmias, smooth muscle hypere:citability, mental dand an:iety states

IN!ICATINS< >ild hypocalcemia3 Antacid @including heartburn, sour stomach, and acid ianithyperphosphatemic

USUAL !SA"E< #ypocalcemia&"utritional supplement M 0.15-0.5 grams 0-8 times daily ithout meals3 antihyperphosphatemic M 5-08 grams daily in divided doses ith meals


28/32

A!#E$SE $EACTINS< After P) use M DI irritation, constipation, headache, mild hyperca@anore:ia, "('

CNT$AIN!ICATINS< !igitali%ed clients, sarcoidosis, renal or cardiac disease, ventricu;brillation, cancer clients ith bone metastases3 renal calculi, hypophosphatemia3 hyperc

NU$SIN" CNSI!E$ATINS< Perform thorough nursing history, noting clinical presenta

indications for therapy, and any precipitating causes3 list drugs prescribed, especially if redigitalis products @may be contraindicated3 monitor calcium levels and renal function3 assor parathyroid disease3 note bone density ;ndings3 supplements need vitamin ! to facilitaabsorption3 report adverse side e=ects, lac/ of desired response, and /eep all follo-up apto evaluate drug response

CLT$I&ALE

CLASSIFICATIN< A"II"*ECI'E3 A"IBI)IC3 A"I*"DA

ACTIN< #as broad-spectrum fungicidal activity. Acts by altering fungal cell membrane pe

permitting loss of phosphorous compounds, potassium, and other essential intracellular co

ith conse$uent loss of ability to replicate.

IN!ICATINS< !ermal infections including tinea pedis, tinea cruris, tinea corporis, tinea v

also vulvovaginal and oropharyngeal candidiasis.

S C S D b l li f i i l d i i


29/32

A!#E$SE $EACTINSDI< Abnormal liver function tests3 occasional nausea and vomiting

troche. S/in< Stinging, erythema, edema, vesication, des$uamation, pruritus, urticaria, s/

;ssures. rogenital< >ild burning sensation, loer abdominal cramps, bloating, cystitis, ur

urinary fre$uency, vulval erythema and itching, pain and vaginal soreness during intercou

INTE$ACTINS!rug: Intraaginal preparations ma* inactiate S+E$&ICI!ES,

CNT$AIN!ICATINS< )phthalmic uses3 systemic mycoses. Safe use during pregnancy

for oral troches, category B for topical preparations, lactation, and in children 8 y not es

NU$SIN" CNSI!E$ATINS-SPA+I"D !I+EICS, A"DI)E"SI"-C)"'E+I"DE"HG>E @ACE I"#IBI)+S may cause hyper/alemia.CNT$AIN!ICATINS< Severe renal impairment3 severe hemolytic reactions3 untreated disease3 crush syndrome3 early postoperative oliguria @e:cept during DI drainage3 adynamacute dehydration3 heat cramps, hyper/alemia, patients receiving potassium-sparing diurinto:ication ith A' conduction disturbance.

NU$SIN" CNSI!E$ATINS< >onitor I() ratio and pattern in patients receiving the parIf oliguria occurs, stop infusion promptly and notify physician. ab test< *re$uent serum el

arranted >onitor for and report signs of DI ulceration @esophageal or epigastric pain or


32/32

arranted.>onitor for and report signs of DI ulceration @esophageal or epigastric pain orhematemesis.>onitor patients receiving parenteral potassium closely ith cardiac monitoheartbeat is usually the earliest clinical indication of hyper/alemia.Be alert for potassium @hyper/alemia, see S(S, Appendi: *3 may result from any therapeutic dosage, and the paasymptomatic.

nursing drug cards

Documents